Yale University is making headlines with significant advancements in medical treatment and biological discovery, alongside its ongoing celebration of the nation's 250th anniversary. The FDA recently cleared the immunotherapy drug teplizumab for pediatric patients with Stage 3 Type 1 diabetes (T1D), a breakthrough stemming from a clinical trial where Yale's Kevan Herold served as senior investigator. Herold has dedicated over 30 years to T1D research.
In biological research, a new Yale study has uncovered significant physiological variance among woodland salamanders, challenging the long-held concept of "evolutionary stasis" for these seemingly identical species. Yale biologist Martha Munoz said, "the diversity was there all along. It just wasn't obvious from what meets the eye." This research reveals hidden complexities in species previously thought to be unchanging.
Furthermore, as the United States celebrates its 250th birthday, Yale, now in its 325th year, is actively honoring and exploring the nation's story, which closely intertwines with its own. The university played a significant role during the American Revolution, a period marked by danger, disruption, and heroism on campus, with many leaders, students, and alumni joining the patriots' cause. Yale News is presenting various ways the institution is examining this shared history.